Stay updated on Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The site footer’s revision label changed from v3.7.0 to v3.7.1. The study record remains inaccessible behind a 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-07T01:09:50.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed, replacing the usual study record content and navigation. As a result, the trial details and related information on this page are not accessible.
    Difference
    21%
    Check dated 2026-09-23T01:12:10.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.7.0, replacing Revision: v3.6.6. This indicates a version update to the study page's documentation.
    Difference
    0.0%
    Check dated 2026-09-16T00:25:51.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The related topics section loses the 'Prostate cancer' tag and the MedlinePlus Genetics link, removing disease tagging and external resource references from the page context.
    Difference
    0.1%
    Check dated 2026-09-08T22:53:49.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The page gains a Prostate cancer tag. It adds a related topics section with MedlinePlus Genetics and updates the page revision from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-09-01T19:52:00.000Z thumbnail image
  8. Check
    51 days ago
    Change Detected
    Summary
    A new line '2016 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, indicating NIH funding attribution for this trial. This addition reflects updated funding information associated with the study.
    Difference
    0.0%
    Check dated 2026-08-25T21:41:52.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial page.